Lifeward and Ottobock Care Test a Scalable U.S. Access Model for ReWalk 7
Lifeward and Ottobock Care are testing a six-month U.S. access model for ReWalk 7. The significance is less about new hardware and more about the clinical, reimbursement and support infrastructure required to turn coverage into actual personal exoskeleton use.
The Exoskeleton Market in 2026: Size, Growth, Companies and Adoption Trends
The exoskeleton market is moving from research and pilots toward commercial scale. This evidence-led 2026 analysis explains market size, industrial and medical adoption, consumer mobility, listed companies, major investments, funding rounds and the outlook to 2030.
Soft Hand Exoskeleton for Severe ALS
A co-designed textile robotic glove enabled a person with severe ALS-related hand impairment to grasp objects and feed himself. The Nature Machine Intelligence study also found that benefit depended strongly on the user’s remaining hand function.